ReviewCancers2022
Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- A phase I/II study of the safety and efficacy of [European journal of nuclear medicine and molecular imaging · 2023Trial
- Development of dual SSTRSC medicinal chemistry · 2026Article
- Cross-Species Quantitative Benchmarking of SSTR2 Radioligands in Fresh-Frozen Brain Sections: An Adaptable Framework for Radiopharmaceutical Development.Molecular imaging and biology · 2026Article
- [EJNMMI physics · 2026Article
- Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution.EJNMMI radiopharmacy and chemistry · 2025Article
- [Current radiopharmaceuticals · 2025Article
- First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([European journal of nuclear medicine and molecular imaging · 2024Article
- Imaging of Pheochromocytomas and Paragangliomas.Endocrine reviews · 2024Review
- SSTR Antagonists as Theranostic Option in Merkel Cell Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [International journal of molecular sciences · 2024Article
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Effective Treatment of SSTR2-Positive Small Cell Lung Cancer UsingMolecular pharmaceutics · 2023Article
- Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.Trends in cancer · 2023Review
- Predicting [EJNMMI physics · 2023Article
- DOTATOC PET/CT imaging of a typical carcinoid tumor in a human ex-vivo perfused lung lobe.Quantitative imaging in medicine and surgery · 2023Article
- Clinical Advances and Perspectives in Targeted Radionuclide Therapy.Pharmaceutics · 2023Review
- Detection of acute myocarditis by ECG-triggered PET imaging of somatostatin receptors compared to cardiac magnetic resonance: preliminary results.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Molecular simulations of SSTR2 dynamics and interaction with ligands.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 (SST
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.